Quarterly Report · 10-Q
Palatin Technologies, Inc.
Quarterly Report
Filed Feb 17, 2026Accepted Feb 17, 2026, 9:30 AM ESTCIK 911216Accession 0001493152-26-006969
Company context
We are a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
Current securities
Historical securities (5)
Registered securities in this filing
PALATIN TECHNOLOGIES, INC. · 10-Q · Filed 2026-02-17
As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.
Common Stock, par value $0.01 per share
- Symbol
- PTN
- Exchange
- NYSEAMER
- Classification
- COMMON
Filing context
Context: From2025-07-01to2025-12-31
Dimensions: Not supplied
Accession 000149315226006969 · 1 registered-security cover member
Read the exact SEC filing ↗As-filed source
Primary evidence